About one-third of participants lost 20 percent or more. LaValle explains that the 16.6 percent average weight loss seen with the Wegovy pill reflects several factors, including the higher 25 mg dose, the 64-week length of the trial, the diet and activity coaching participants received and the strong biological effects of semaglutide as a GLP-1
Available from: [Last accessed on 2025 Sep 24, Last updated on 2024 Feb 20]
Ohanian M, Zhang H, Pemmaraju N, Rice W, Howell S, Tang G, Bueso-Ramos C, Borthakur G, Andreeff M
Based on current clinical evidence, tirzepatide (Zepbound) produces the highest average weight loss, followed by semaglutide (Wegovy), and then liraglutide (Saxenda)
This might be for a brand-name GLP-1 like Ozempic or Wegovy, or a compounded version if your insurance doesnt cover the brand